Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.
Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. Vivas-Mejia P, et al. Among authors: sanguino a. Clin Cancer Res. 2010 Jan 1;16(1):184-94. doi: 10.1158/1078-0432.CCR-09-1180. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028751 Free PMC article.
Strategies for in vivo siRNA delivery in cancer.
Sanguino A, Lopez-Berestein G, Sood AK. Sanguino A, et al. Mini Rev Med Chem. 2008 Mar;8(3):248-55. doi: 10.2174/138955708783744074. Mini Rev Med Chem. 2008. PMID: 18336345 Review.
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Landen CN, et al. Among authors: sanguino am. Cancer Biol Ther. 2006 Dec;5(12):1708-13. doi: 10.4161/cbt.5.12.3468. Epub 2006 Dec 30. Cancer Biol Ther. 2006. PMID: 17106249
Targeting SRC in mucinous ovarian carcinoma.
Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK. Matsuo K, et al. Among authors: sanguino am. Clin Cancer Res. 2011 Aug 15;17(16):5367-78. doi: 10.1158/1078-0432.CCR-10-3176. Epub 2011 Jul 7. Clin Cancer Res. 2011. PMID: 21737505 Free PMC article.
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK. Stone RL, et al. Among authors: sanguino am. Cancer Biol Ther. 2014 Jul;15(7):919-29. doi: 10.4161/cbt.28882. Epub 2014 Apr 23. Cancer Biol Ther. 2014. PMID: 24755674 Free PMC article.
Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.
Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Gray MJ, et al. Among authors: sanguino am. Oncogene. 2008 Dec 4;27(57):7192-200. doi: 10.1038/onc.2008.356. Epub 2008 Sep 22. Oncogene. 2008. PMID: 18806828 Free PMC article.
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G. Fernández A, et al. Among authors: sanguino a. J Clin Invest. 2007 Dec;117(12):4044-54. doi: 10.1172/JCI32373. J Clin Invest. 2007. PMID: 18060038 Free PMC article.
37 results